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Medicare Reimbursement for Total Joint
Arthroplasty: The Driving Forces
Eric M. Padegimas, MD, Kushagra Verma, MD, Benjamin Zmistowski, MD, Richard H. Rothman, MD, PhD,
James J. Purtill, MD, and Michael Howley, PhD
Investigation performed at The Rothman Institute, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Background: Total joint arthroplasty is a large and growing part of the U.S. Medicare budget, drawing attention to how much
providers are paid for their services. The purpose of this study was to examine the variables that affect total joint arthroplasty
reimbursement. Along with standard economic variables, we include unique health-care variables. Given the focus on value in
the Affordable Care Act, the model examines the relationship of the quality of care to total joint arthroplasty reimbursement.
We hoped to ﬁnd that reimbursement patterns reward quality and reﬂect standard economic principles.
Methods: Multivariable regression was performed to identify variables that correlate with Medicare reimbursement for total
joint arthroplasty. Inpatient charge or reimbursement data on Medicare reimbursements were available for 2,750 hospitals
with at least 10 discharges for uncomplicated total joint arthroplasty from the Centers for Medicare & Medicaid Services
(CMS) for ﬁscal year 2011. Reimbursement variability was examined by using the Dartmouth Atlas to group institutions into
hospital referral regions and hospital service areas. Independent variables were taken from the Dartmouth Atlas, CMS, the
WWAMI (Washington, Wyoming, Alaska, Montana, Idaho) Rural Health Research Center, and the United States Census.
Results: There were 427,207 total joint arthroplasties identiﬁed, with a weighted mean reimbursement of $14,324.84
(range, $9,103 to $38,686). Nationally, the coefﬁcient of variation for reimbursements was 0.19. The regression model
accounted for 52.5% of reimbursement variation among providers. The total joint arthroplasty provider volume (p < 0.001)
and patient satisfaction (p < 0.001) were negatively correlated with reimbursement. Government ownership of a hospital
(p < 0.001) and higher Medicare costs (p < 0.001) correlated positively with reimbursement.
Conclusions: Medicare reimbursements for total joint arthroplasty are highly variable. Greater reimbursement was
associated with lower patient volume, lower patient satisfaction, a healthier patient population, and government ownership of a hospital. As value-based reimbursement provisions of the Affordable Care Act are implemented, there will be
dramatic changes in total joint arthroplasty reimbursements. To meet these changes, providers should expect qualities
such as high patient volume, willingness to care for sicker patient populations, patient satisfaction, safe outcomes, and
procedural demand to correlate with their reimbursement.
Clinical Relevance: Practicing orthopaedic surgeons and hospital administrators should be aware of discrepancies in
inpatient reimbursement for total joint arthroplasty from Medicare. Furthermore, these discrepancies are not associated
with typical economic factors. These ﬁndings warrant further investigation and collaboration between policymakers and
providers to develop value-based reimbursement.

Peer review: This article was reviewed by the Editor-in-Chief and one Deputy Editor, and it underwent blinded review by two or more outside experts. It was also reviewed
by an expert in methodology and statistics. The Deputy Editor reviewed each revision of the article, and it underwent a ﬁnal review by the Editor-in-Chief prior to publication.
Final corrections and clariﬁcations occurred during one or more exchanges between the author(s) and copyeditors.

M

edicare reimbursement in total joint arthroplasty is a
large part of U.S. federal health-care spending. In 2010,
1.05 million total joint arthroplasties were performed

in the United States, with a total cost of approximately $20 billion1,2. Furthermore, the incidence of this procedure is projected
to increase exponentially as the American population ages and the
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online version of the article, one or more of the authors checked “yes” to indicate that the author had a relevant ﬁnancial relationship in the biomedical
arena outside the submitted work and “yes” to indicate that the author had other relationships or activities that could be perceived to inﬂuence, or have
the potential to inﬂuence, what was written in this work.
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Affordable Care Act (ACA) is implemented3. An older and less
healthy population undergoing total joint arthroplasty will likely
require greater health-care resources because of an expected increase in complications4-8. Additionally, the ACA should expand
access to care for about 10% of the population9, which should
increase the demand for total joint arthroplasty 10.
The ACA is taking action to cut health-care costs and to
increase price transparency 11-13. One speciﬁc measure enacted by
the Centers for Medicare & Medicaid Services (CMS) was the
public release of inpatient charge and reimbursement data14. This
makes public the mean Medicare reimbursement, inpatient
charges, and provider volume for the 100 most commonly billed
inpatient procedures. Although release of these data was intended
to clarify health-care billing, incomplete analysis by the public
media has actually made the true details of hospital reimbursement
patterns more obscured15-18. The public media have focused on
those physicians and hospitals at the extremes of reimbursement,
shifting the focus away from what variables may actually be driving
reimbursement patterns as a whole.
Given the increasing demand for total joint arthroplasty
and rising costs of health care in the context of the increasing
transparency of hospital reimbursement, expanded access to care,
and price regulation of the ACA9,10, we attempted to analyze what
variables drive Medicare reimbursement patterns. The purpose of
this study was to identify geographic, socioeconomic, and healthcare quality variables that were associated with higher reimbursement for total joint arthroplasty. The time period of study is ﬁscal
year 2011, before the implementation of the ACA. This is important because these results will provide a baseline by which we can
understand how much total joint arthroplasty reimbursement will
likely change after the implementation of the ACA.
Materials and Methods

T

his study analyzes variables associated with reimbursement to hospitals
for uncomplicated primary total joint arthroplasty, diagnosis-related group
14
(DRG) number 470 . Only providers that submitted 10 or more cases designated
with DRG 470 are included in this data set, which identiﬁed 2,750 hospitals. DRG
469, complicated primary major joint replacement, and DRGs 466 to 468 (revision
arthroplasty codes) were excluded with the intention of minimizing interprocedural
variability that may contribute to reimbursement variability. Reimbursement is
deﬁned by the CMS database as all payments made to the hospital for the entire stay
related to DRG 470 by Medicare. Although analysis by Current Procedural Terminology (CPT) codes would have been preferable to distinguish primary hip arthroplasty from primary knee arthroplasty, the CMS only published reimbursement
data by DRG in this data set. Regional analysis was performed by dividing the 2,750
providers into 306 hospital referral regions (regional level) and 1,785 hospital service
19,20
areas (local level) using their operating zip code with the Dartmouth Atlas .
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relative to the cost of care. As a result, quality of care is critical to value-based
9
reimbursement as described in the ACA . Data on quality of care were collected
from the CMS and through the Hospital Consumer Assessment of Healthcare
23,24
Providers and Systems (HCAHPS) Survey . These metrics include readmission
rate, complications or deaths, patient satisfaction, and surgical volume. Readmission and complication or death rates adjusted by age, sex, and comorbidities
within 30 days of total joint arthroplasty were published by the CMS at the individual hospital level. Patient satisfaction assessments of each provider through the
HCAHPS Survey were published by CMS at the individual hospital level. This
reports the percentage of patients who gave the hospital an overall score of 9 or 10
of 10. Finally, total joint arthroplasty volume was reported in the primary CMS data
set at the individual hospital level. Volume was treated as a continuous variable, and
the number of patients discharged in 2011 with DRG 470 was considered a hospital’s volume. We included volume as a quality measure, as it has been repeatedly
25-29
shown that higher-volume surgeons and hospitals have improved outcomes .

Economic Drivers
Traditional economic variables were also included in the model to explain
changes in reimbursement. The Dartmouth Atlas was utilized to identify basic
economic (supply and demand) variables. This data source was queried for data
on the number of service providers, availability of hospital beds, and total
Medicare reimbursements adjusted for age, sex, and race for each speciﬁc
19
hospital service area . Provider-speciﬁc total joint arthroplasty volume was
reported in the CMS data. The regional incidence of total joint arthroplasty was
deﬁned as the provider-speciﬁc volume data from the primary CMS data aggregated by hospital service area per 1,000 Medicare enrollees in the area.
The availability of alternatives to total joint arthroplasty should also affect
the reimbursement. In traditional economic terms, this factor is often described
as the availability of substitutes. Variables that could offer substitutes for total
joint arthroplasty were identiﬁed with the Dartmouth Atlas and CMS. These
included the total supply of physicians who could provide nonoperative therapy
and the number of regional outpatient physical therapy ofﬁces that could provide
nonoperative treatment for degenerative arthritis. Competition could also affect
reimbursement for total joint arthroplasty. The amount charged for total joint
arthroplasty by neighboring institutions offers insight into the local market environment. The mean charges of the neighboring hospitals were calculated for
each provider and were included in the model to account for both geographic
variation in reimbursement and the impact of neighboring providers’ behavior.
Neighboring hospitals were considered to be those within the provider’s hospital
referral region. Furthermore, each institution was classiﬁed as urban, large rural
city or town, small rural town, or isolated small rural town using the WWAMI
22
Rural Health Research Center data .

Patient Metrics

The independent variables were collected from 4 sources: the United States Census
21
14
19
Bureau ; CMS ; the Dartmouth Atlas ; and the Washington, Wyoming, Alaska,
22
Montana, Idaho (WWAMI) Rural Health Research Center . They were then
grouped into 7 subcategories: quality, demand, supply, alternatives to total joint
arthroplasty (substitutes), competitive factors, patient characteristics, and provider characteristics, as shown in the Appendix.

Data on patient characteristics were collected using census data and were aggregated by hospital service area. The Dartmouth Atlas was utilized to determine
19
all zip codes in each hospital service area . The available economic characteristics
for these zip codes were tabulated as weighted means by total population from
30
the 2008 to 2012 American Community Survey for each hospital service area.
The data from this analysis describe the general population’s health insurance
status, employment status, education level, overall health, and income level. The
metric used to study overall health of the patient population is the hierarchical
condition category, which is a score reported as hospital referral region-speciﬁc
data by CMS that describes the prevalence of chronic conditions within the
31
provider’s region . Additionally, this data set provided regional information
regarding the frequency and cost of inpatient stays for Medicare beneﬁciaries
older than 65 years of age in each hospital referral region. Finally, the proportion
of beneﬁciaries with arthritis in each hospital referral region was also reported in
this data set as a measure of disease burden for total joint arthroplasty.

Quality Metrics

Provider Metrics

Given the emphasis on value-based reimbursement in the ACA, we include
quality indicators in the model. Value is measured as the level of quality of care

The provider characteristics were taken from CMS data . Hospital ownership
was categorized into government-owned (at the state, local, or federal level),

Independent Variables

32
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TABLE I The Most Clinically and Economically Relevant Variables Analyzed
Variable

Dollars of Deviation from Mean Reimbursement*

P Value

Quality
Readmission rate in percent

105.15

0.147

Complication or mortality rate in percent
Patient satisfaction in percent

283.1
228.53

0.252
<0.001‡

21,066.08†

Volume in cases

<0.001‡

Demand
20.001

Arthritis burden in percent
Total Medicare enrollees in cases

0.013
273.97

Total joint arthroplasty per 1,000 Medicare enrollees

1
<0.001‡
0.351

Supply
No. of orthopaedic surgeons

2.5

0.92

Patient characteristics
29,208

Patient comorbidities§
Percentage of patients with private insurance

<0.001‡

262.44

<0.001‡

20.02
2106

<0.001‡
0.001‡

2.98

<0.001‡

736.86

<0.001‡

Competitive factors
Neighbor charges
No. of neighboring providers
Medicare inpatient per-capita costs
Provider characteristics
Provider ownership (compared with nonproﬁt)
Government

2637.7

Proprietary

21,408

Physician
Provider charges

0.02

<0.001‡
0.001‡
<0.001‡

*For the beta coefﬁcient, positive values correspond to dollars greater than the mean reimbursement and negative values correspond to dollars
less than the mean reimbursement per the unit of the variable measured. †Logarithmic transformation of variable for kurtosis. ‡These independent drivers of Medicare reimbursements were determined to be signiﬁcant. §Hierarchical condition category.

proprietarily-owned, physician-owned, voluntary nonproﬁt, or unknown.
When computing the multivariable regression model for reimbursements, the
mean provider charges were included as an independent variable.

Data Analysis and Statistical Model
The data were screened for missingness and normality. All variables were missing
<5% of data points and were mean-replaced except for the rate of readmission
(8.0%) and the rate of complication or death (8.6%), which were >5%. The
missing data for these two variables were imputed. All variables that did not have
acceptable normality were log-transformed. SPSS Statistics (version 20.0; IBM)
and Microsoft Excel 2013 were utilized for all statistical calculations.
The multivariable linear regression had Medicare reimbursement as the
dependent variable and independent variables of quality, demand, supply, alternatives to total joint arthroplasty, competitive factors, patient characteristics,
and provider characteristics. The model was run in blocks by independent variable grouping (as described above) with the previous grouping variables included in the running of the subsequent group. We report both p values and
unstandardized coefﬁcients (b) that are equivalent to the dollars of deviation
from mean reimbursement attributed to that variable, independently of all other
variables. A greater absolute value of b equates to a greater increase in dollars
reimbursed associated independently with a unit increase of that variable.
With the release of subsequent ﬁscal year inpatient charges, reimbursement, and discharges for 2012 and 2013, an opportunity to investigate variation
in year-to-year mean reimbursement was possible. Therefore, Pearson correla-

tion of volume and reimbursement was performed. Furthermore, to validate
the ﬁndings of the constructed model, reimbursement and discharge data from
ﬁscal year 2012 (October to September) were substituted and the impact of each
variable grouping was reassessed. From this analysis, it was found that total discharges billed to CMS by individual providers were highly correlated (p < 0.001)
between 2011 and 2012 (R = 0.98) and between 2011 and 2013 (R = 0.96).
Furthermore, the mean reimbursement for major joint arthroplasty was highly
correlated (p < 0.001) between 2011 and 2012 (R = 0.90) and between 2011 and
2013 (R = 0.87).

Results
Reimbursement Variability
he CMS data set identiﬁed 427,207 total joint arthroplasties
performed nationally, with a weighted mean reimbursement
to the hospital of $14,324.84 (range, $9,103.27 to $38,686.28).
Reimbursement variability (measured by coefﬁcient of variation) at the national level was 0.19. Reimbursements became
less variable at the regional and local levels, with coefﬁcients
of variation of 0.12 by hospital referral region and of 0.11 by
hospital service area. A map of the weighted means of Medicare
reimbursements in individual hospital referral regions (Fig. 1)
shows the geographic variability in Medicare reimbursement.
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Fig. 1

A map of the United States divided into regions (hospital referral region) with weighted means of Medicare reimbursements. Regions with higher mean
reimbursements appear in brown.

Variables Associated with Reimbursement
The model explained 52.5% (R2 = 0.525) of variability in reimbursement. This was validated with ﬁscal year 2012 data (R2 = 0.557)

and ﬁscal year 2013 data (R2 = 0.542). The largest variable groups
accounting for variation were competitive factors (12.8%), patient
characteristics (10.9%), and supply (10.0%). Validation with ﬁscal

Fig. 2

Percentage of Medicare reimbursement variability explained by the predictive regression model.
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year 2012 data found that these variable groups still accounted for
the most variation in reimbursement providers. Quality factors
had little impact on reimbursement, accounting for only 4.8%
of variability (Fig. 2). When looking at independent variables
that correlated with hospital reimbursement for total joint
arthroplasty, it was found that decreased patient satisfaction
(b = 228.53; p < 0.001), decreased provider volume (logarithmic variable, b = 21,066.08; p < 0.001), and a more healthy
patient population (b = 29,208; p < 0.001) paradoxically correlated with increased reimbursements (Table I). Other notable
variables independently associated with increased reimbursement
were a lower proportion of privately insured patients (b = 262.44;
p < 0.001), government hospital ownership (b = 736.86; p <
0.001), increased provider charges (b = 0.02; p < 0.001), and
increased Medicare costs (b = 2.98; p < 0.001) (Table I). Medicare
reimbursements were expectedly higher with increased costs, but
unexpectedly, for every dollar in increased cost, a hospital was
reimbursed nearly $3 more for that stay ($2.98 deviation from the
mean reimbursement). Each variable was examined for association with reimbursements independently of all other variables
studied. The multivariable regression model does not account for
whether or not these independent variables had a compounding
effect when analyzed in combinations. Univariate analysis of the
relationship of provider charges to Medicare reimbursement revealed a mild but signiﬁcant correlation (R = 0.210; p < 0.001).
The Appendix contains all variables included in this model and
their associated signiﬁcance.
Discussion
he multivariable regression model of Medicare reimbursement variability designed in this study utilized a number of
variables to account for quality, demand, supply, substitutes for
total joint arthroplasty, patient characteristics, competitive factors, and provider characteristics. This model explained just over
half of the variation in reimbursement patterns. Notably, many
of the metrics that independently correlated with increased
government payment ran contrary to patterns expected from a
system that rewards quality and follows basic economic principles. Quality metrics such as high patient satisfaction and patient
volume25-29 were inversely correlated with Medicare reimbursement. Hospitals that treated in regions with a sicker patient
population received lower reimbursements, despite the fact that
sicker patient populations typically have worse clinical outcomes
with longer and more costly hospital stays and increased complications4,5,8,33,34. Unexpectedly, government ownership of a hospital
was also independently associated with higher reimbursements.
Finally, more costly care was rewarded with higher reimbursements. Although we expected this result, as reimbursements
account for hospital costs, the proportion of increase was unexpected. For every additional dollar of hospital cost, Medicare
reimbursed $2.98 more, a nearly threefold increase. The variables identiﬁed by this model suggest that lower cost-efﬁciency,
lower quality, and government ownership all paradoxically correlate with higher reimbursements.
Since the release of the data set used in this study, the
CMS has increased efforts to release more detailed billing in-
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formation. In April 2014, Medicare reimbursements were released at the individual provider level35. Following the release of
these data, a number of journalists across the nation attempted
to analyze these numbers for the general public15-18,35-37. The
public release of this information with interpretation by the lay
press has increased scrutiny on reimbursements to individual
providers and institutions. However, this public analysis emphasized the outliers rather than looking at those factors that
correlate with reimbursements as a whole15,16,18,35,36. Our multivariable regression model attempted to look comprehensively
at the socioeconomic, quality, and efﬁciency variables that are
really driving reimbursements. If the ﬁndings of this model are
accurate, it is likely that health-care policy makers are not
emphasizing quality and economic principles, as reimbursement patterns do not reﬂect these variables. Alternatively, if the
ﬁndings that are based on these large, publicly available data
sets are inaccurate, these should not be presented to the general
public without more stringent analysis applied.
The major limitations of this study were a result of the
source data sets. First, these data were public and therefore
nonidentiﬁable. Consequently, individual case characteristics
were unknown and may have contributed to reimbursement
variability in ways not explored in this analysis. We attempted
to control for this by only analyzing DRG 470. Although the
proportion of patients at each institution who underwent a hip
arthroplasty compared with those who underwent a knee arthroplasty was not speciﬁed by DRG 470 alone, this DRG only
included primary arthroplasty (revisions are DRG 466 to 468)
and did not include patients with a major complication or
comorbidity (as delineated by DRG 469). Therefore, use of only
DRG 470 should have limited a large degree of interprocedural
variability. Further analysis by International Classiﬁcation of
Diseases, Ninth Revision (ICD-9) or CPT code might have
yielded more speciﬁc results; however, these data were not
available for public consumption. Additionally, the independent variables had different scopes; some variables applied to
individual hospitals, some variables applied to hospital service
areas, and other variables applied to hospital referral regions
(as enumerated in the Appendix). The variables were used to
correlate with reimbursement to individual hospitals, so the
variables that applied to the hospital service area or hospital
referral region may not have truly represented the nuances
among different hospitals in the same region. However, different hospitals within the same catchment area should have
been treating similar patient populations and should have been
exposed to similar local economic climates. These differences
in the scope of independent variables and lack of accounting for
interprocedural variability may have accounted for at least a
part of the 47.5% of reimbursement variability that was not
accounted for in this model. Furthermore, analysis of this data
set did not allow for comparison of those cases that may have
triggered outlier ﬂags by hospitals and may have resulted
in greater reimbursement. It is possible that a hospital had
a disproportionate number of outlier cases, as discussed by
Li et al., requiring greater resources and therefore resulted in
signiﬁcantly elevated reimbursement that could not be factored
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into this analysis38. However, this should have been captured by
the quality measures and the overall health (hierarchical condition category) of patients. Finally, although the independent
variables selected for our model were selected with the goal of
being comprehensive, there may have been other drivers of
reimbursement variability that were not anticipated.
In conclusion, Medicare reimbursements for total joint
arthroplasty are highly variable. Greater reimbursement was
associated with lower patient volume, lower patient satisfaction,
a healthier patient population, and government ownership of a
hospital. There will be dramatic changes in total joint arthroplasty reimbursements as value-based reimbursement provisions of the ACA are implemented. To meet these changes,
hospitals should expect qualities such as high patient volume,
willingness to care for sicker patient populations, patient satisfaction, safe outcomes, and procedural demand to drive their
reimbursement. It is our hope that this analysis has shed light on
a complicated and controversial topic that strongly affects how
the medical community is perceived by the general public.
Appendix
Tables showing all independent variables included in the
multivariate regression model with their source as well as
results of the multivariate regression model utilizing all variables
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are available with the online version of this article as a data
supplement at jbjs.org. n
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